论文部分内容阅读
目的观察阿德福韦酯联合拉米夫定对乙肝肝硬化患者的临床疗效及转化生长因子-β1(TGF-β1)和白介素-8(IL-8)的影响。方法将90例乙肝肝硬化患者随机分为治疗组和对照组，每组45例；在常规治疗的基础上，治疗组给予阿德福韦酯联合拉米夫定治疗，对照组单一给予阿德福韦酯治疗；6个月后检测患者的肝功能指标，评定临床疗效，并采用酶联免疫吸附(ELISA)法测定两组患者治疗前后血清中 TGF-β1、IL-8水平变化。结果治疗组临床总有效率为88.89%，明显高于对照组的71.11%(P<0.05)；两组患者血清中肝功能指标白蛋白(ALB)水平增加，谷丙转氨酶(ALT)、谷草转氨酶(AST)水平降低，其血清细胞因子TGF-β1、IL-8水平也均较治疗前降低，差异有统计学意义(P<0.05或P<0.01)，且上述指标的改善观察组优于对照组(P<0.05或P<0.01)。结论阿德福韦酯联合拉米夫定治疗乙肝肝硬化疗效可靠，其对肝脏的保护作用可能与调节血中TGF-β1、IL-8水平有关。“,”Obj ective]To observe clinical efficacy of adefovir dipivoxil combined with lamivudine for the treatment of patients with hepatitis B liver cirrhosis and its effect on transforming growth factor-β1 (TGF-β1 ) and interleukin-8(IL-8).[Methods]A total of 90 patients with hepatitis B liver cirrhosis were randomly divided into treatment group and control group with 45 patients in each group.On the basis of routine therapy,the treatment group was given adefovir dipivoxil combined with lamivudine,while the control group received ade-fovir dipivoxil treatment.Liver function indexes were detected after 6 months.Clinical efficacy was assessed. ELISA was used to detect the change of TGF-β1 and IL-8 in serum of 2 groups before and after treatment.[Results]Total effective rate in treatment group was 88.89%,which was obviously higher than that in control group(71.11%)(P<0.05).The content of liver function index ALB in serum of patients in two groups was increased,but ALT and AST were reduced.Compared with before treatment,the serum levels of cytokines TGF-β1 and IL-8 were also decreased,and there was significant difference(P<0.05 or P <0.01).The im-provement of above indexes in observation group was better than control group(P<0.05 or P<0.01).[Con-clusion]adefovir dipivoxil combined with lamivudine for the treatment of hepatitis B liver cirrhosis has reliable efficacy.Its protective effect on liver may be related to the regulation of TGF-β1 and IL-8 levels in blood.